Agoracom Blog Home

Posts Tagged ‘Cannabis’

Vertical Exploration Launches ”CEO Verified” Discussion Forum on AGORACOM to Act as Primary Investor Social Media Platform

Posted by AGORACOM at 10:00 AM on Monday, February 4th, 2019
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564648/hub/vertical.png

VANCOUVER, BC / February 4, 2019 / VERTICAL EXPLORATION INC. (TSX-V: VERT) (“Vertical” or “the Company”) is pleased to announce the launch of a “CEO Verified” Discussion Forum on AGORACOM. The forum will serve as the Company’s primary social media platform to interact with both shareholders and the broader investment community in a fully moderated environment.

The Company will also receive significant exposure through millions of content brand insertions on the AGORACOM network and extensive search engine marketing over the next 12 months. In addition, exclusive sponsorships of invaluable digital properties such as AGORACOM TV, the AGORACOM home page and the AGORACOM Twitter account will serve to significantly raise the brand awareness of the Corporation among small cap investors.

MODERATED DISCUSSION FOR PUBLIC COMPANY EXECUTIVES AND SHAREHOLDERS

AGORACOM “CEO Verified” provides the first ever identity verification of small cap executives on a finance platform. For the first time ever, small cap CEO’s and other company officers can post or communicate within a discussion forum without the risk of impersonation leading to catastrophic consequences. As the ultimate influencers of their own companies, “CEO Verified” Forums will create incredible levels of engagement between companies and investors that have long desired civilized, constructive and factual conversation, with no limitations as to the number of characters.

Posts to AGORACOM are shareable on Twitter, Facebook and LinkedIn, which enables the Company to continue utilizing these channels while making AGORACOM the primary HUB of investor engagement.

There are no log-in requirements for investors to visit the forum and read posts. Those wishing to post questions, comments and interact with company officers can quickly log-in using their Facebook or LinkedIn accounts, or create an anonymous new user account.

The Vertical Discussion Forum can be found at:

https://agoracom.com/ir/verticalexploration

Verified officer at launch:

  • Peter P. Swistak, President/CEO

Peter P. Swistak stated, “Social media participation is very important for growth companies such as ours and AGORACOM forums are purpose built to facilitate intelligent discussion without the nonsense that plagues other such sites. I encourage everyone to read and participate in our CEO Verified Discussion Forum to create great, vibrant and constructive discussion for the long term benefit of everyone.”

George Tsiolis, AGORACOM Founder, stated, “This is a service that is long overdue for small cap companies, executives and long-term shareholders that have had no choice but to watch their company message get hijacked on unmonitored forums by unscrupulous investors. CEO Verified Discussion Forums is the killer solution and it is free, so every small cap CEO in North America should be using it and every small cap shareholder should be demanding it.”

SHARES FOR SERVICES

The Company intends to issue common shares in the capital of the Company (the “Common Shares“) to AGORA in exchange for the Services. Pursuant to the terms of the Agreement, the Company will be issuing a total fee of $60,000 (plus HST), to be paid as follows:

  • $60,000 + HST to be paid via Shares for Services
  • $12,000 + HST Shares for Services upon Commencement February 1, 2019 for initial set up of HUB, marketing materials and search engine programs.
    • $12,000 + HST Shares for Services at end of Third Month May 1, 2019
    • $12,000 + HST Shares for Services at end of Sixth Month August 1, 2019
    • $12,000 + HST Shares for Services at end of Ninth Month November 1, 2019
    • $12,000 + HST Shares for Services at end of Twelfth Month February 1, 2020

The number of Common Shares to be issued at the end of each period will be determined by using the closing price of the Common Shares of the Company on the Toronto Venture Exchange (“TSX-V“) on the first trading day following the end of each period for which the Services were provided by AGORA.

The term of the Agreement is for 12 months effective February 1, 2019 and the agreement is subject to TSX-V approval.

ABOUT VERTICAL EXPLORATION

Vertical Exploration’s mission is to identify, acquire, and advance high potential mining prospects located in North America for the benefit of its stakeholders. The Company’s flagship St-Onge Wollastonite property is located in the Lac-Saint-Jean area in the Province of Quebec.

About AGORACOM

AGORACOM is the pioneer of online marketing, broadcasting, conferences and investor relations services to North American small and mid-cap public companies, with more than 300 companies served. AGORACOM is the home of more than 767K investors that visited 5.2 million times and read 53 million pages of information every year. The average duration of visit of 8min 43sec is more than double that of global financial sites, which can be attributed to the implementation and enforcement of the strongest moderation rules in the industry (All Metrics Average 2008 – 2017).

AGORACOM traffic ranks within the top 0.5% of all websites around the world. These traffic results are independently tracked and verified by Google analytics. AGORACOM traffic can be attributed to its strategy of maintaining the cleanest, moderated small-cap discussion, as well as, implementation of the first ever Investor Controlled Stock Discussion Forums in 2007. 10 years later, in 2017, AGORACOM launched the first ever “CEO Verified” Discussion Forums to allow Small Cap CEO’s and Company officers to post comments in a fully verified, moderated and social media shareable environment.

For further information, please contact:

AGORACOM

Web: www.agoracom.com

Email: [email protected]

ON BEHALF OF THE BOARD
_________________________________
Peter P. Swistak, President

FOR FURTHER INFORMATION PLEASE CONTACT:

Telephone: 1-604-683-3995
Toll Free: 1-888-945-4770

CLIENT FEATURE: Applied BioSciences Stands to Deliver Aquiring Majority Stake in Trace Analytics $HTIM $WMD.ca

Posted by AGORACOM at 11:40 AM on Friday, January 11th, 2019
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564626/hub/APPB_logo.png
  • Acquired a majority stake in Trace Analytics, Inc., a leading testing and analytics company.
  • The team has over 65 years of experience in the testing and analytics space and a full-time staff of nine employees including, two Ph.D. analytical chemists and five other scientists. 
  • A recent report from Coherent Market Insights1 estimates that the global cannabis testing market is projected to grow 13.2% year-over-year through 2026, when it is expected to surpass $1.5 billion USD.
  • Applied BioSciences products use base ingredients that are USDA Organic and non-GMO. Offering Vegan, sugar-free, 99% Pure CBD Isolate infused. The products are formulated with CBD extracted from pesticide-free, organically grown, domestically produced, High-CBD Industrial Hemp. Lab-tested and guaranteed Pesticide and Chemical-free.  Our proprietary blends also contain USDA certified organic botanicals, herbals and essential oils to provide synergy with other healing elements found in nature.
  • On December 20, 2018, President Trump signed the US Farm Bill into law. The new law defines hemp as an agricultural product for the first time in 50 years and allows American farmers to plant and harvest hemp. This will allow farmers and researchers of hemp to receive the same benefits as farmers and researchers of other crops, including the ability to apply for insurance and federal grants
  • Applied BioSciences early stage investment in Hightimes Magazine is valued at approximately $1.75 Million at assumed IPO Pricing of $11.00

Link to AppliedSciences Hub

FULL DISCLOSURE: Applied BioSciences is an advertising client of AGORA Internet Relations Corp.

$APPB Applied Biosciences Acquires Majority Stake in Cannabis Testing Firm $BOG.ca $NBUD.ca $MCOA $APPB$AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Posted by AGORACOM at 10:27 AM on Wednesday, January 9th, 2019
  • Acquired a majority stake in Trace Analytics, Inc., a leading testing and analytics company
  • Estimates of the Global cannabis testing market is projected to grow 13.2% year-over-year through 2026
  •  Applied BioSciences continues to be at the forefront of the evolving consumer market, using organically grown plants, without pesticides or herbicides as our main ingredient

(January 9, 2018) Los Angeles, CA – Applied Biosciences Corp. (OTCQB: APPB), a diversified cannabinoid therapeutics company focused on the medical, bioceutical and pet health industries, announced that it has acquired a majority stake in Trace Analytics, Inc., a leading testing and analytics company. The team has over 65 years of experience in the testing and analytics space and a full-time staff of nine employees including, two Ph.D. analytical chemists and five other scientists. 

A recent report from Coherent Market Insights1 estimates that the global cannabis testing market is projected to grow 13.2% year-over-year through 2026, when it is expected to surpass $1.5 billion USD.

Although the health benefits of Cannabis and CBD are becoming well known, one of the challenges is the safety and testing of these products which are ingested, vaped and applied topically.  Many products in the market are cheaply-made, with multiple toxins, chemicals and synthetics.   Some of the products include high levels of THC, harmful substances, illegally processed synthetic cannabinoids, and even some that have no CBD at all. Applied Biosciences intends to position Trace as the leading provider of testing solutions for both compliance requirements and consumer safety.

 â€œApplied BioSciences continues to be at the forefront of the evolving consumer market, using organically grown plants, without pesticides or herbicides as our main ingredient.  As the company, continues to expand our product lines it is important to know that our products have been thoroughly tested by trusted labs in the industry for chemicals, pesticides and any harmful materials.  All our products are tested to ensure high-caliber and quality as well as overall safety.  We will now be able to test our products in an expedited fashion as well as from third-party labs and continue to provide the highest standard of testing results and safety protocols on all our products.” commented Chris Bridges, President of Applied BioSciences Corp.

“Applied BioSciences will allow our company and team to expand. We are excited to embark on this new partnership.  Both organizations have a focus on quality and providing the end user the safest possible products.   The leadership teams of both companies have decided to expand the testing offerings to include advanced pesticide testing by purchasing a gas chromatography tandem mass spectrometer (GC/MS/MS) to complement the liquid chromatography tandem mass spectrometer (LC/MS/MS), as well as purchasing an ion coupled plasma mass spectrometer (ICP/MS) for heavy metals testing. These new platforms, once certified, will allow Trace Analytics to certify Washington State’s medical grade cannabis as well as offering advanced analytical testing to the CBD producers / processors from around the world.”  commented Jason Zitzer, COO of Trace Analytics Inc.

Applied BioSciences products use base ingredients that are USDA Organic and non-GMO. Offering Vegan, sugar-free, 99% Pure CBD Isolate infused. The products are formulated with CBD extracted from pesticide-free, organically grown, domestically produced, High-CBD Industrial Hemp. Lab-tested and guaranteed Pesticide and Chemical-free.  Our proprietary blends also contain USDA certified organic botanicals, herbals and essential oils to provide synergy with other healing elements found in nature.

1 Coherent Market Insights – https://www.coherentmarketinsights.com/market-insight/cannabis-testing-market-170

About Applied BioSciences Corp.

Applied BioSciences Corp. (www.appliedbiocorp.com), is a diversified company focused on multiple areas of the medical, bioceutical and pet health industry. As a leading company in the CBD and Pet health space, the company is currently shipping to the majority of US states as well as to 5 International countries.  The company is focused on select investment, consumer brands, and partnership opportunities in the recreational, health and wellness, nutraceutical, and media industries.

The company has several strategic partnerships and investments currently in place and is actively pursuing additional partnerships and strategic growth opportunities.

About Trace Analytics Inc.

Trace Analytics Inc. is a leading cannabis science and technology company with significant footprints in lab testing, research and development and licensing. Trace Analytics was started by a group of scientists who specialized in analytical chemistry, genetics and molecular biology.  The focus of the team is to ensure compliance with public safety standards and end user safety. Trace Analytics is in the process of expanding throughout the United States, and globally. With the goal of helping the rest of the world adopt “best practices” in cannabis and hemp testing, the company also provides expert consulting services to legislators and regulators in many countries, states and municipalities around the world. For more information, please visit: http://traceanalytics.com

Contact

Email: [email protected]  or [email protected]

To be added to the Applied BioSciences email distribution list, please email [email protected] with APPB in the subject line.

Official Website: www.appliedbiocorp.com / www.traceanalytics.com

Brands:

www.remedishop.com

www.herbalpet.com

www.canagel.com

Follow us:

Facebook @remedicbd & @HerbalPetMeds

Instagram @remedishop & @herbal_pet

Twitter @remedishop & @herbal_pet

Tetra Bio-Pharma $TBP.ca Pilot Study to Investigate a Cannabinoid Derived Drug in Dogs $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:55 AM on Thursday, November 15th, 2018

Logo tetrabiopharma rgb web

Tetra Bio-Pharma and Panag Pharma Advance their Veterinary Drug Pipeline 

  • Announced the submission of a clinical research application to the Veterinary Drugs Directorate at Health Canada.
  • This first of a kind veterinary study will examine the use of a cannabinoid-based drug to treat ocular pain and inflammation in canines
  • The pilot study will be led by veterinary ocular care specialists

ORLEANS, Ontario, Nov. 15, 2018 — Tetra Bio-Pharma Inc. (“Tetra” or “TBP”) (TSX VENTURE: TBP) (OTCQB: TBPMF) and Panag Pharma Inc. (“Panag”) today announced the submission of a clinical research application to the Veterinary Drugs Directorate at Health Canada. This first of a kind veterinary study will examine the use of a cannabinoid-based drug to treat ocular pain and inflammation in canines. The pilot study will be led by veterinary ocular care specialists.

“Several companies are marketing cannabis-based treatments for aliments in companion animals, but there is a major gap in understanding the safety and efficacy of these drugs,” said Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma. “This study demonstrates our commitment to becoming a world leader in the field of cannabinoid-based therapies for vision health. Tetra continues to adhere to an evidence-based drug development model, consistent with bringing novel, efficacious and safe drug products to market, including the veterinary market. We look forward to launching this trial to investigate the use of cannabinoids to treat eye pain and inflammation in dogs.”

In addition to the pharmaceutical and natural health products markets, Tetra will also launch trials in the companion animal market.  If approved, these products will be destined for global sales. At present, world-wide revenues derived from the companion animal market exceeded $30 billion in 2017, and this is expected to grow to $41 billion by 2024.

About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including this trial, the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Bougainville Ventures $BOG.ca arranges $1M private placement $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 12:08 PM on Wednesday, November 14th, 2018

681747 5720 copy 2

  • Arranged a private placement of units at a price of 20 cents per unit for gross proceeds of up to $1-million.
  • Company has made an allowance for an oversubscription of up to 100 per cent of the expected gross proceeds of $1-million

Bougainville Ventures Inc. has arranged a private placement of units at a price of 20 cents per unit for gross proceeds of up to $1-million. The company has made an allowance for an oversubscription of up to 100 per cent of the expected gross proceeds of $1-million.

Each unit comprises one common share of the company and one common share purchase warrant. Each warrant entitles the holder to purchase one additional common share of the company at an exercise price of 30 cents per warrant share for a term that is 24 months from the date of closing of the private placement.

The proceeds of the private placement will be used for general working capital.

The company wishes to correct a typo in its news release dated Oct. 31, 2018, in which it announced the closing of a previously announced private placement with gross proceeds of $308,000 and 1,232,000 units. The previously announced private placement closed with gross proceeds of $320,500 and 1,282,000 units.

About Bougainville Ventures Inc.

Bougainville provides cannabis infrastructure and seed-to-sale services to I-502 tenant-growers leasing greenhouse facilities space and providing fully built out, turnkey solutions and ancillary services including processing, cannabis expertise, and marketing and sales resources. Greenhouse canopies provide a 50-per-cent saving in cultivation cost.

We seek Safe Harbor.

Revenues at #Cannabis Startups Surge as Demand Begins to Outstrip Supply $BOG.ca $NBUD.ca $MCOA $ACG.ca $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 10:51 AM on Wednesday, November 14th, 2018

By Kevin Kelleher

7:30 PM EST

Three of the largest cannabis companies reported earnings this week, painting a portrait of a nascent industry enjoying surging demand as recreational pot becomes legalized in more places—but they’re also encountering some growing pains.

Aurora Cannabis said Monday its revenue rose 260% to $29.7 million Canadian dollars (US$22 million). Net income came in at C$105.5 million, up from C$3.56 million a year ago, largely because of unrealized gains on securities.

On Tuesday, Tilray said revenue rose 86% to C$10 million, while its net loss increased to C$19 million from C$1.8 million a year ago, driven largely by an increase in non-cash stock-based compensation charges.

Also on Tuesday, Cronos Group said revenue in the third quarter rose 186% to C$3.8 million, compared with C$1.3 million a year ago. Cronos lost 4 Canadian cents per share.

Both Tilray and Cronos said that the average price of weed per gram declined. Tilray attributed the decline to an increase in bulk sales as a percentage of total revenue.

However, the price of cannabis could increase in the future because demand is beginning to outstrip supply as Canada and many U.S. states have legalized marijuana. Much of the cannabis sales the three companies reported last quarter came from medicinal marijuana.

“Similar to other Canadian LPs, we are facing demand that outstrips supply,” Aurora’s chief corporate officer Cam Battley said during the company’s earnings conference call. “We anticipate this dynamic to continue for some time.”

Cannabis stocks surged through most of 2018 before encountering a selloff, once pot became legal in Canada, in a classic buy-on-rumor, sell-on-news scenario. Investors appear to be remaining cautious, despite the strong revenue growth last quarter. On Tuesday, Aurora’s stock on the NYSE fell 3.7%, while TIlray fell 1.9% and Cronos fell 1.7%.

Source: http://fortune.com/2018/11/13/revenue-cannabis-startups-surges-demand-outstrip-supply/

$BOB.ca Bougainville Ventures to Purchase Additional Property in Washington State $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM at 1:07 PM on Thursday, October 18th, 2018
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564641/hub/681747-5720_copy_2.jpg
  •  Entered into an agreement with Green Venture Capital Corp., to purchase the balance of a 4 acre property in Oroville, Washington.
  • Future plans for the property include multi-tenant greenhouse structures.
  • A report by the Rand organization suggests that there are currently up to 650,000 recreational marijuana users in Washington State, worth approximately $1.25 – $1.5 Billion USD in annual sales.

 Vancouver, BC, Canada – October 17, 2018, BOUGAINVILLE VENTURES INC. (“Bougainville” or the “Company”) (CSE:BOG) (“Bougainville” or the “Company”) is pleased to announce it has entered into an agreement with Green Venture Capital Corp., to purchase the balance of a 4 acre property in Oroville, Washington.

The Company currently owns a one acre parcel of land that is occupied by a Tier -3, I-502 tenant. This transaction will add another 3 acres to the Oroville Campus. Once this transaction is completed the Company will have purchased the 4 acre parcel of land in Whatcom County, Washington State for a total purchase price of $350,000.00 USD. The Company now has up to 30 days to complete its due diligence. During this due diligence period the Company will work with its architect to develop future plans for the property that will include multi-tenant greenhouse structures.

The property meets all the Company’s criteria for its planned expansion into Washington State on it Oroville Campus. The property is permitted for both agricultural and light industrial production and processing uses, and currently contains two buildings totaling 1,700 sq. ft. and a 1,000 sq. ft. workshop/garage with sufficient room for expansion.
Andy Jagpal, President of Bougainville, commented that, “The addition of this property in Washington State will help the Company achieve its strategic goals and objectives to facilitate expansion of its Oroville Campus.”

About the Washington I-502 Marijuana Market In November 2012, the Washington State Liquor Control Board (WSLCB) passed Initiative 502 (I-502) pursuant to a vote by the people of the State of Washington. I-502 authorized the WSLCB to regulate and tax recreational marijuana products for persons over twenty-one years of age and thereby created a new industry for growing, processing and selling of Washington State-regulated recreational marijuana products. A recent WSLCB commissioned report by the Rand organization suggests that there are currently up to 650,000 recreational marijuana users in Washington State, worth approximately $1.25 – $1.5 Billion USD in annual sales.

About Bougainville Ventures, Inc.  Bougainville provides cannabis infrastructure and seed-to-sale services to I-502 tenant-growers leasing greenhouse facilities space and providing fully built-out, turnkey solutions and ancillary services including processing, cannabis expertise and marketing and sales resources. Greenhouse canopies provide a 50% saving in cultivation cost. Bougainville has 30,000 sq.ft., in near production in Oroville, WA.
For more information please visit: http://bougainvilleinc.com/

On behalf of the Board of Directors BOUGAINVILLE VENTURES INC.

Andy Jagpal, CEO and Director

For further information, please contact Andy Jagpal at [email protected] or 1-844-734-8420

Namaste $N.ca $NXTTF Announces Supply Agreement with Kief #Cannabis $VAPE $VPCO $MCIG $ABCN.ca $ACG.ca $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 8:41 AM on Wednesday, August 29th, 2018

  • Company has signed a wholesale supply agreementwith Manitoba-based, late-stage ACMPR applicant, Kief Cannabis Company Ltd.
  • Under the terms of the Supply Agreement, Namaste will purchase bulk cannabis products under the Company’s wholly-owned subsidiary, Cannmart Inc. to offer in its online platform

VANCOUVER, Aug, 29, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (TSXV: N) (FRANKFURT: M5BQ) (OTCMKTS: NXTTF) is pleased to announce that the Company has signed a wholesale supply agreement (the “Supply Agreement”) with Manitoba-based, late-stage ACMPR applicant, Kief Cannabis Company Ltd. (“Kief Cannabis” or “kiefcannabis.ca”). Under the terms of the Supply Agreement, Namaste will purchase bulk cannabis products under the Company’s wholly-owned subsidiary, Cannmart Inc. (“Cannmart”) to offer in its online platform.

Kief Cannabis is focused on developing high-quality artisan-crafted cannabis products with a specific focus on the best plant genetics and a refined production process that is designed to deliver high-grade, small-batch craft product. Kief Cannabis will focus on the high-end recreational market with premium quality cannabis. Through the Supply Agreement with Namaste, Kief Cannabis will position in itself for national exposure by offering its products through Cannmart’s online marketplace and in having their products for sale along with other leading Canadian cultivators who are participating in Namaste’s platform.

With NamasteMD’s (“NamasteMD.com“) patient database growing at an exponential rate, and with Cannmart’s sales license imminent, the Company has successfully secured guaranteed supply through agreements with its cultivation partners. Due to its rapid and accelerating growth rate, NamasteMD’s clinic team has expanded to accommodate the influx of patient consultations. Namaste has already established itself as the largest global online marketplace for cannabis consumption devices and has over 1.5 Million customers globally. The Company has developed and uses industry leading e-commerce technology including on-site AI through its wholly owned subsidiary, Findify AB (“Findify.io”), that personalizes the online user experience for every customer.

Cannmart’s platform, following the same strategy will offer patients access to the largest variety of cannabis products sourced from multiple vendors in a single location. With innovations like NamasteMD, Findify and Cannmart’s online platform, the Company has created a fully-integrated patient experience from prescription to delivery. Cannmart will be one of the first online retailers to offer same-day delivery service through its partner, Pineapple Express Delivery Inc. (“Pineapple Express”), starting with the Greater Toronto Area (GTA) and expanding across the country. This Supply Agreement represents further progress in Namaste positioning itself as Canada’s leader for cannabis e-commerce and technology. The Company has received immense support from its cultivation partners that validate Namaste’s platform and strategy.

Management Commentary

Jesse Denton, CEO of Kief Cannabis comments: “Namaste has positioned itself very strategically to become Canada’s top cannabis retailer online and their business model is supported by their success in e-commerce both in Canada and international markets. I’m very pleased for Kief Cannabis to be aligned with such a major player, and look forward to a long-term working relationship with the Namaste team.”

Sean Dollinger, President and CEO of Namaste comments: “We’re very pleased to announce this Supply Agreement with Kief Cannabis. We’ve spent significant time in discussion with their team and believe strongly in our ability to market and sell craft cannabis brands in our platform. We believe that consumers should have access to the best selection of high quality product and we’re focused on building relationships with craft brands like Kief Cannabis who will create more value for our patients online.

Ultimately, everything we’re doing is focused on creating a personalized and amazing user experience. All of the technology we’ve developed has been centered around this concept. The more value we can bring to our customers, whether through NamasteMD, AI integrations or the best possible customer service, Namaste has years of experience operating in the online market and that is what I believe sets us apart from our competitors.

We’re also very proud that our cultivator partners across the country see value in Namaste’s platform and marketplace. We believe that the online market for medical and recreational cannabis will evolve rapidly in Canada and that Namaste is well-positioned with extensive expertise to be the number one online platform for everything cannabis not only in Canada but globally.”

About Kief Cannabis

Kief Cannabis was established as a corporation in December of 2013 under the laws of the Province of Manitoba with the goal of producing and delivering craft-style cannabis to the Canadian marketplace. On March 16, 2018, Health Canada provided a Confirmation of Site Readiness letter to Kief Cannabis, and the company has been recognized by the Liquor and Gaming Authority of Manitoba (to be renamed the Liquor, Gaming and Cannabis Authority of Manitoba) as an upcoming supply chain within the Province of Manitoba.

Kief Cannabis is comprised of passionate and determined individuals who will strive: i) to collectively provide exceptionally high quality small-batch craft cannabis strains to recreational users across Canada; and ii) to create an environmentally-friendly, socially responsible and Canadian-owned company. The initial product line will consist of internationally exclusive and rare strains of cannabis and oils, with the intent to expand into vape-pens, rosins and edible products as they become legal in Canada. Kief Cannabis’ unique variety of cannabis strains will appeal to those seeking a more exclusive, premier product with a small-batch craft feel.

Kief Cannabis is currently in its Series A funding stage and intends to raise the capital needed to complete the construction of a state-of-the-art cultivation facility located in Selkirk Manitoba. Once completed, Kief Cannabis shall utilize refined procedures throughout the entire production process to develop exceptionally high-grade products for its end-users.

About Namaste Technologies Inc.

Namaste Technologies is Your Everything Cannabis Store™. Namaste operates the largest global cannabis e-commerce platform with over 30 websites in 20+ countries under various brands. Namaste’s product offering through its subsidiaries includes vaporizers, glassware, accessories, CBD products, and the company will soon be selling medical cannabis in the Canadian market, subject to approval by Health Canada.

Namaste has developed and acquired innovative technology platforms including NamasteMD.com, Canada’s first Health Canada compliant telemedicine application, and in May 2018 the Company acquired a leading e-commerce AI and Machine Learning Company, Findify AB. Findify uses artificial intelligence algorithms to optimize and personalize a consumer’s on-site buying experience. Namaste is focused on leveraging its cutting-edge technology to enhance the user experience throughout its platforms. Namaste will continue to develop and acquire innovative technologies which will provide value to the Company and to its shareholders as well as to the broader cannabis market.

On behalf of the Board of Directors

“Sean Dollinger”

Chief Executive Officer

Direct: +1 604-355-6100

Email: [email protected]

Further information on the Company and its products can be accessed through the links below:

NamasteTechnologies.com

NamasteMD.com

NamasteVapes.ca

Everyonedoesit.ca

FORWARD-LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The TSXV has neither reviewed nor approved the contents of this press

View original content with multimedia:http://www.prnewswire.com/news-releases/namaste-announces-supply-agreement-with-kief-cannabis-300704020.html

SOURCE Namaste Technologies Inc.

Namaste $N.ca $NXTTF announces supply agreement with #Bonify and acquisition of over 14,000 registered users with #NamasteMD $VAPE $VPCO $MCIG $ABCN.ca $ACG.ca $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 9:14 AM on Wednesday, August 22nd, 2018

  • Signed a wholesale supply agreement with Manitoba-based ACMPR Licensed producer, Bonify Inc.
  • Under the terms of the Supply Agreement, Namaste will purchase bulk cannabis products through the Company’s wholly-owned subsidiary, Cannmart Inc

VANCOUVER, Aug. 22, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (TSXV: N) (FRANKFURT: M5BQ) (OTCMKTS: NXTTF) is pleased to announce that the Company has signed a wholesale supply agreement (the “Supply Agreement”) with Manitoba-based ACMPR Licensed producer, Bonify Inc. (“Bonify”). Under the terms of the Supply Agreement, Namaste will purchase bulk cannabis products through the Company’s wholly-owned subsidiary, Cannmart Inc. (“Cannmart”).  Bonify operates a large-scale cultivation facility and will expand capacity to over 350,000 square-foot that will accommodate Namaste’s growth trajectory. Namaste will work with Bonify to develop private-label strains of cannabis for the medical and recreational markets as well as in offering the full selection of Bonify products.

Further to the Company’s August 13th news release, Cannmart completed its Health Canada Pre-Sales inspection on July 31st, 2018 and the receipt of its “sales-only” license will represent a major milestone for the Company. With Cannmart’s “sales-only” license imminent, and in order to accommodate the acceleration of NamasteMD’s (NamasteMD.com) database and with the launch of Canadian recreational cannabis sales pending, the Supply Agreement with Bonify will guarantee adequate supply to support Namaste’s demand.

Namaste is also pleased to announce that it has registered over 14,000 users in its online patient portal and mobile app, NamasteMD representing a 130% increase in registered users in approximately 2 months. With the latest launch of the NamasetMD app, the Company has streamlined the on-boarding process, improved conversion rates and has opened the app’s scheduling to accommodate appointments within 15 minutes from sign-up. The accelerated growth in patient acquisition which has taken place over the past two and a half months is extremely encouraging. Namaste anticipates seeing further acceleration once Cannmart’s sales license is received and cannabis sales are integrated within the platform.

The Company is also pleased with initial results from the launch of its patient feedback app, Uppy Strain Journal (“Uppy”), with over 11,000 downloads from its launch one month ago. Data collection through Uppy will drive machine learning algorithms that will be used in tandem with cannabis strain data to provide better strain recommendations for medical patients. By adding value for medical patients in an online environment, Namaste will achieve lower cost per patient acquisition, higher conversion rates, increased revenue and provide a better user experience.

Namaste’s e-commerce platform and technology will continue to drive innovation that will have a major impact on the way in which patients can access medical cannabis online. Namaste’s goal is to create the most comprehensive user experience possible by personalizing product and strain recommendations through integration of its AI technology, providing convenient access to healthcare practitioners through its patient portal, NamasteMD, and to drive cannabis sales through Cannmart.

Management Commentary

Dalbir Bains, President and CEO of Bonify comments: “We are thrilled to be partnering with the leading cannabis technology company in Canada.  We have witnessed firsthand the impact Namaste MD is having on patients by providing the most convenient and accessible health care experience regardless of whether you live in an urban or rural market thanks to its telehealth capabilities.  The addition of Cannmart, which is coming shortly, will truly complete the patient experience from symptom to diagnosis, from a health care practioner, to receiving a product that will improve the quality of the patient’s life.  This aligns with Bonify’s mission of improving the lives of our patients”.

Sean Dollinger, President and CEO of Namaste comments: “We’re very excited to be working with Bonify and their team. I was personally on-site at their facility in Winnipeg and was very impressed with their operations and the quality of their products. Bonify will be a strong supply partner for Namaste as they understand our vision and have significant capacity to support our growing patient network. We’re in a key position now where many of our efforts are coming together with our anticipated sales license at Cannmart. We’re looking forward to expanding on our relationship with Bonify in the future and are very excited to be seeing all of these pieces now coming together. The Agreement with Bonify will ensure supply availability for Namaste during a period going in to recreational legalization where many producers anticipate a supply shortage.

I’m very happy to see incredible results in our progress with NamasteMD and Uppy. These platforms will provide Namaste with long term value in domestic and international markets. We will continue to focus on developing our e-commerce platform to encompass everything cannabis. We’re very excited for the future, looking forward to receiving our sales license soon and in rolling-out Cannmart’s platform. We believe that Namaste will emerge as the dominant leader in cannabis e-commerce sales globally and have already established the infrastructure to achieve this goal.”

About Bonify Inc.

Bonify is a Canadian-owned Licensed Producer and leading provider of medical cannabis. By maximizing research findings and strictly adhering to best-in-class practices, quality standards and procedures, Bonify produces medical cannabis products to help individuals get the most out of life each and every day. With over 1,000,000 square feet of potential productive capacity at its present site in Winnipeg, Manitoba, Canada, when at full scale, Bonify will be capable of growing over 100,000 kg of cannabis annually. For more information, visit www.bonify.com.

About Namaste Technologies Inc.

Namaste Technologies is Your Everything Cannabis Store™. Namaste operates the largest global cannabis e-commerce platform with over 30 websites in 20+ countries under various brands. Namaste’s product offering through its subsidiaries includes vaporizers, glassware, accessories, CBD products, and the company will soon be selling medical cannabis in the Canadian market, subject to approval by Health Canada.

Namaste has developed and acquired innovative technology platforms including NamasteMD.com, Canada’s first Health Canada compliant telemedicine application, and in May 2018 the Company acquired a leading e-commerce AI and Machine Learning Company, Findify AB. Findify uses artificial intelligence algorithms to optimize and personalize a consumer’s on-site buying experience. Namaste is focused on leveraging its cutting-edge technology to enhance the user experience throughout its platforms. Namaste will continue to develop and acquire innovative technologies which will provide value to the Company and to its shareholders as well as to the broader cannabis market.

On behalf of the Board of Directors

“Sean Dollinger”

Chief Executive Officer

Direct: +1 (604) 355 6100

Email: [email protected]

Further information on the Company and its products can be accessed through the links below:

NamasteTechnologies.com

NamasteMD.com

NamasteVapes.ca

Everyonedoesit.ca

FORWARD-LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The TSXV has neither reviewed nor approved the contents of this press release.

View original content with multimedia:http://www.prnewswire.com/news-releases/namaste-announces-supply-agreement-with-bonify-and-acquisition-of-over-14-000-registered-users-with-namastemd-300700862.html

Tetra Bio-Pharma $TBP.ca Announces Initiation of Coverage by Paradigm Capital $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 4:06 PM on Monday, August 13th, 2018

Logo tetrabiopharma rgb web

  • Announced that Paradigm Capital, an independent investment banking and advisory group, based in Toronto, has initiated research coverage of Tetra Bio-Pharma.
  • Coverage by Paradigm represents another step forward as Tetra Bio-Pharma increases its visibility in the capital markets.

ORLEANS, Ontario, Aug. 13, 2018 – Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE:TBP) (OTCQB:TBPMF), today announced that Paradigm Capital, an independent investment banking and advisory group, based in Toronto, has initiated research coverage of Tetra Bio-Pharma.

Today’s initiation of coverage by Paradigm represents another step forward as Tetra Bio-Pharma increases its visibility in the capital markets.

To access the report, visit Tetra Bio-Pharma’s Investors section of its website under Analysts: http://tetrabiopharma.com/investors/analysts/default.aspx

About Paradigm Capital Inc.

Paradigm Capital Inc. (PCI) is a research-driven, independent, institutional equity investment dealer focused on sectors and companies that have attractive long-term secular growth prospects. PCI’s research is available on our website at www.paradigmcap.com

About Tetra Bio-Pharma Inc.

Tetra Bio-Pharma (TSX-V:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.

Robert (Bob) Bechard
Executive Vice President, Corporate Development and Licensing
514-817-2514
[email protected]